pentaerythritol tetra(3-mercaptopropionate): structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 82056 |
| CHEMBL ID | 3183062 |
| SCHEMBL ID | 56208 |
| MeSH ID | M0486201 |
| Synonym |
|---|
| 7575-23-7 |
| pentaerythritol tetrakis(3-mercaptopropionate), >95% |
| pentaerythritol tetrakis(3-mercaptopropionate) |
| FT-0696314 |
| pentaerythritol tetra(3-mercaptopropionate) |
| P0886 |
| [3-(3-sulfanylpropanoyloxy)-2,2-bis(3-sulfanylpropanoyloxymethyl)propyl] 3-sulfanylpropanoate |
| 6m5413vh6n , |
| pentaerythrityl tetrakis(3-mercaptopropionate) |
| unii-6m5413vh6n |
| propanoic acid, 3-mercapto-, 2,2-bis((3-mercapto-1-oxopropoxy)methyl)-1,3-propanediyl ester |
| propanoic acid, 3-mercapto-, 1,1'-(2,2-bis((3-mercapto-1-oxopropoxy)methyl)-1,3-propanediyl) ester |
| ec 231-472-8 |
| einecs 231-472-8 |
| NCGC00256305-01 |
| dtxsid1044728 , |
| cas-7575-23-7 |
| dtxcid9024728 |
| 3-[(3-sulfanylpropanoyl)oxy]-2,2-bis{[(3-sulfanylpropanoyl)oxy]methyl}propyl 3-sulfanylpropanoate |
| tox21_301513 |
| eh-317 |
| qx-40 |
| petmp |
| 3-((3-sulfanylpropanoyl)oxy)-2,2-bis(((3-sulfanylpropanoyl)oxy)methyl)propyl 3-sulfanylpropanoate |
| pemp |
| pos-405 |
| q-43 |
| eh-316 |
| propanoic acid, 3-mercapto-, 2,2-bis[(3-mercapto-1-oxopropoxy)methyl]-1,3-propanediyl ester |
| SCHEMBL56208 |
| d-arg-pro-lys-pro-gln-gln-d-trp-phe-d-trp-leu-leu-nh2hydrochloride |
| CHEMBL3183062 |
| mfcd00022104 |
| JOBBTVPTPXRUBP-UHFFFAOYSA-N |
| 2,2-bis((3-mercaptopropanoyloxy)methyl)propane-1,3-diyl bis(3-mercaptopropanoate) |
| Q27265140 |
| AS-81682 |
| pentaerythritol-tetrakis-3-mercaptopropionate |
| CS-0310540 |
| HY-W250309 |
| F71212 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 61.6448 | 3.1890 | 29.8841 | 59.4836 | AID1224846 |
| AR protein | Homo sapiens (human) | Potency | 6.1083 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 0.0069 | 0.0002 | 29.3054 | 16,493.5996 | AID743075 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 12.7137 | 0.1434 | 27.6121 | 59.8106 | AID1159516; AID1159519 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 61.6448 | 0.0420 | 27.3789 | 61.6448 | AID743210 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 54.8442 | 0.0006 | 27.2152 | 1,122.0200 | AID743202; AID743219 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 37.3970 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 16 (80.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.43) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 20 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||